Streetbeat News

Revenues

KELYA

Kelly Services (NASDAQ:KELYA) reported Q2 2024 adjusted EPS of $0.71, beating the $0.56 estimate by 26.79%. Sales were $1.057 billion, surpassing the $1.048 billion estimate but down 13.15% from last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:33 am

NVMI

Nova provided its financial outlook for Q3 2024, expecting revenue between $168M and $176M, significantly higher than the estimated $148.1M. The company also anticipates adjusted EPS between $1.60 and $1.73, surpassing the estimated $1.36.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:33 am

HGV

Hilton Grand Vacations (NYSE:HGV) reported Q2 2024 earnings of $0.02 per share, missing the analyst estimate of $0.90 by 97.78%. Sales were $1.24 billion, missing the $1.31 billion estimate by 5.92%, but up 22.64% from last year's $1.01 billion.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:32 am

PH

Parker Hannifin (NYSE:PH) reported Q4 2024 adjusted EPS of $6.77, beating the $6.22 estimate. Sales were $5.200 billion, surpassing the $5.082 billion estimate and showing a 2.04% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:31 am

NVMI

Nova reported Q2 2024 adjusted EPS of $1.61, beating the estimate of $1.36. Sales were $156.858 million, surpassing the expected $148.119 million.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:31 am

KOPN

Kopin (NASDAQ:KOPN) reported Q2 2024 adjusted EPS of $(0.05), missing the $(0.04) estimate, but achieved sales of $12.23M, beating the $9.94M estimate. Sales increased by 16.88% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:31 am

FOUR

Shift4 has raised its FY24 gross revenue less network fees outlook from $1.30B - $1.35B to $1.35B - $1.38B and tightened the high end of its end-to-end payment volume range.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:30 am

IMCR

Immunocore Holdings (NASDAQ:IMCR) reported better-than-expected Q2 2024 results with a GAAP EPS of $(0.23), beating the estimate of $(0.45). Sales also surpassed expectations, reaching $75.4 million, a 24.21% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:25 am

VITL

Vital Farms has raised its FY24 revenue guidance to at least $590 million, up from $575 million, surpassing the $585.76 million estimate. The company also increased its adjusted EBITDA guidance to at least $75 million from $70 million.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:25 am

ALT

Altimmune (NASDAQ:ALT) reported Q2 2024 GAAP EPS of $(0.35), missing the $(0.34) estimate and showing a 9.37% increase in losses from the previous year. Sales were $5.000K, down 16.67% YoY.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 11:23 am